Identification of a unique form of p53 in human cord blood associated with the development of maternal autoantibodies

American Journal of Reproductive Immunology

Volumn 39, Issue 6, 1998, Pages 368-375

  Yashar, Catheryn M ^a   Gerçel Taylor, Çiçek ^a   Gibb, Randall K ^a   Weeks, Jonathan W ^a,b   Taylor, Douglas D ^a  

^a University of Louisville School of Medicine   (United States)

^b LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

Alternative splicing; Autoimmunity; Development; p53

Indexed keywords

AUTOANTIBODY; MATERNAL ANTIBODY; PROTEIN P53;

ARTICLE; AUTOIMMUNITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL MOBILITY SHIFT ASSAY; HUMAN; IMMUNOBLOTTING; MULTIPARA; NORMAL HUMAN; OVARY CANCER; PRIORITY JOURNAL; UMBILICAL CORD BLOOD;

EID: 0345647096     PISSN: 87558920     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0897.1998.tb00371.x     Document Type: Article

References (31)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991; 253:49-53.
2. Lin J, Wu X, Chen J, Chang A, Levine AJ: Function of p53 protein in growth regulation and tumor suppression. Cold Spring Harb Symp Quant Biol 1994; 59:215-223.
3. Haidacher S, Blaschitz A, Desoye G, Dohr G: Immunohistochemical evidence of p53 protein in human placenta and choriocarcinoma. Hum Reprod 1995; 10:983-988.
4. Angelopoulou K, Diamandis EP, Sutherland DJ, Kellen JA, Bunting PS: Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994; 58:480-487.
5. Vojtesek B, Kovarik J, Dolezalova H, Nenutil R, Havlis P, Brentani RR, Lane DR: Absence of p53 autoantibodies in a significant proportion of breast cancer patients. Br J Cancer 1995; 71:1253-1256.
6. Lubin R, Schlichtholz B, Luc Teillaud J, Garay E, Bussel A, Wild C, Soussi, T: p53 antibodies in patients with various types of cancer: Assay, identification and characterization. Clin Cancer Res 1995; 1:1463-1469.
7. Trivers GE, Cawley HL, DeBenedetti VMG, Hollstein M, Marion MJ, Bennett WP, Hoover ML, Prives C, Tamburro C, Harris CC: Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Natl Cancer Inst 1995; 87:1400-1407.
8. Wild C, Ridanpaa M, Anttila S, Lubin R, Soussi T, Husgafvel-Pursiainen K, Vainio, H: p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue. Int J Cancer 1995; 64:176-181.
9. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F, Soussi T: The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 1992; 52:6380-6384.
10. Bourhis J, Lubin R, Roche B, Koscielny S, Bosq J, Dubois I, Talbot M, Marandas P, Schwaab G, Wibault P, Luboinski B, Eschwege F, Soussi T: Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 1996; 88:1228-1232.
11. Roncalli M, Bulfamante G, Viale G, Springall DR, Alfanco R, Comi A, Maggioni M, Polak JM, Coggi G: C-myc and tumour suppressor gene product expression in developing and term human trophoblast. Placenta 1994; 15:399-409.
12. Marzusch K, Ruck P, Horny HP, Dietl J, Kaiserling E: Expression of p53 tumour suppressor gene in human placenta: An immunohistochemical study. Placenta 1995; 16:101-104.
13. Janerich DT: The influence of pregnancy on breast cancer risk. Med Hypoth 1980; 6:1149-1155.
14. Janerich DT: The fetal antigen hypothesis for breast cancer, revisited. Med Hypoth 1994; 43:105-110.
15. Laemmli UK: Cleavage of structural proteins during the as- sembly of the head of the bacteriophage T4. Nature 1970; 227:680-685.
16. Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtesek B, Kaye SB: Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 1993; 55:678-684.
17. Hupp TR, Meek DW, Midgley CA, Lane DP: Regulation of the specific DNA binding function of p53. Cell 1992; 71:875-886.
18. Bartek J, Bartkova J, Lukas J, Staskova Z, Vojtesek B, Lane DP: Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J Pathol 1993; 169:27-34.
19. Flaman JM, Waridel F, Estreider A, Vannier A, Limacher JM, Gilbert D, Iggo R, Frebourg T. The human tumour suppressor gene p53 is alternatively spliced in normal cells. Oncogene 1996; 12:813-818.
20. Bargonetti J, Friedman PN, Kern SE, Vogelstein B, Prives C: Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 1991; 65:1083-1091.
21. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51:6304-6311.
22. Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B: Identification of p53 as a sequence specific DNA binding protein. Science 1991; 252:1708-1711.
23. Clarke AR, Gledhill S, Hooper ML, Bird CC, Wyllie AH: p53 dependence of early apoptotic and proliferative responses within the mouse intestinal epithelium following gamma-irradiation. Oncogene 1994; 9:1767-1773.
24. Matlashewski G, Pim D, Banks L, Crawford L: Alternative splicing of human p53 transcripts. Oncogene Res 1987; 1:77-85.
25. Rehberger PA, Richter KH, Schwanz D, Goldfinger N, Oskato R, Almog N, Marks F, Rotter V: Differential expression of the regularly spliced wild-type p53 and its COOH-terminal alternatively spliced form during epidermal differentiation. Cell Growth Differ 1997; 8:851-860.
26. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T: p53 is required for radiation induced apoptosis in mouse thymocytes. Nature 1993; 362:847-849.
27. Caelles C, Heimberg A, Karin M: p53-dependent apoptosis in the absence of p53-target genes. Nature 1994; 370:220-223.
28. Haupt Y, Rowan S, Shaulian E, Vousden K, Oren M: Induction of apoptosis in HeLa cells by transactivation-deficient p53. Genes Dev 1995; 9:2170-2183.
29. Akcali KC, Khan SA, Moulton BC: Effect of decidualization on the expression of bax and bcl-2 in the rat uterine endometrium. Endocrinology 1996; 137:2123-3131.
30. Friedlander P, Haupt Y, Prives C, Oren M: Amutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol 1996; 16:4961-4971.
31. Hockenberry DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ: Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991; 88:6961-6966.